A Dual Enhancing Strategy of Novel Nanovaccine Based on TIM3 Silencing Nanoadjuvants and Desialylated Cancer Cell Membrane Antigens for Personalized Vaccination Immunotherapy of Cancer
Source abstract
Abstract
Abstract Cancer vaccines represent a promising form of immunotherapy employed in the treatment of cancer. However, their efficiency in eliciting immune responses is limited, and satisfactory results have yet to be achieved. Optimizing adjuvants and antigens is an important approach to promoting the anti‐tumor efficacy of cancer vaccines. Here, a novel nanoadjuvant (LNP/siRNA) designed to silence T‐cell immunoglobulin and mucin‐domain containing‐3 (TIM3) and activate Toll‐like receptors (TLRs) is presented. The LNP/siRNA demonstrates significant potential in promoting dendritic cell (DC) maturation and enhancing the anti‐tumor response. Furthermore, desialylated cancer cell membrane is utilized as antigens, providing a variety of tumor antigens for DCs and enhancing their function. Additionally, they are integrated to create a core‐shell structured nanovaccine (dClip‐LNP/siRNA) through coextrusion, which collectively enhances the cross‐presentation ability of DCs, thus achieving a dual enhancement strategy. The dClip‐LNP/siRNA significantly silences TIM3 expression in DCs and promotes antigen presentation by DCs. Besides, dClip‐LNP/siRNA significantly promotes the activation of T cells in lymph nodes and induces robust and durable anti‐tumor immunity in tumor sites to eliminate established B16‐OVA tumors, prevent tumor occurrence, and suppress tumor lung metastasis. The dClip‐LNP/siRNA is also suitable for combination with adoptive OT‐I cell therapy to enhance cancer immunotherapy. The dClip‐LNP/siRNA represents a robust vaccine platform for personalized cancer immunotherapy.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Immunotherapy and Immune Responses · Monoclonal and Polyclonal Antibodies Research · Bacteriophages and microbial interactions
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutics National Vaccine Innovation Platform School of Pharmacy Nanjing Medical University Nanjing 211166 China
Department of Geriatric Gastroenterology The First Affiliated Hospital of Nanjing Medical University Nanjing 210009 China
College of Chemistry and Chemical Engineering Nanjing University Nanjing 210023 China
Funding
Nanjing Medical University · Jiangsu Provincial Key Research and Development Program · National Natural Science Foundation of China
References (69)
Show source-provided references
1. 10.1126/science.342.6165.143210.1126/science.342.6165.1432 ↗
2. 10.1146/annurev-immunol-100311-10283910.1146/annurev-immunol-100311-102839 ↗
3. 10.1038/s41585-023-00739-w10.1038/s41585-023-00739-w ↗
4. 10.1016/j.addr.2021.11392710.1016/j.addr.2021.113927 ↗
5. 10.1038/s41467-019-13368-y10.1038/s41467-019-13368-y ↗
6. 10.1038/s41577-019-0210-z10.1038/s41577-019-0210-z ↗
7. 10.3389/fimmu.2018.0039410.3389/fimmu.2018.00394 ↗
8. 10.1038/nbt103510.1038/nbt1035 ↗
9. 10.1002/advs.20230012110.1002/advs.202300121 ↗
10. 10.1038/s41586-023-06063-y10.1038/s41586-023-06063-y ↗
11. 10.1172/jci.insight.9836810.1172/jci.insight.98368 ↗
12. 10.1007/s00262-012-1334-110.1007/s00262-012-1334-1 ↗
13. 10.1016/j.ccell.2017.11.01910.1016/j.ccell.2017.11.019 ↗
14. 10.3389/fimmu.2019.0132510.3389/fimmu.2019.01325 ↗
15. 10.1016/j.immuni.2021.04.01910.1016/j.immuni.2021.04.019 ↗
16. 10.1038/s41586-021-03626-910.1038/s41586-021-03626-9 ↗
17. 10.1016/j.immuni.2016.05.00110.1016/j.immuni.2016.05.001 ↗
18. 10.1038/ni.237610.1038/ni.2376 ↗
19. 10.1021/acsnano.2c1079710.1021/acsnano.2c10797 ↗
20. 10.1016/j.addr.2021.11410710.1016/j.addr.2021.114107 ↗
21. 10.1186/s12967-022-03714-y10.1186/s12967-022-03714-y ↗
22. 10.1038/ni.353510.1038/ni.3535 ↗
23. 10.1073/pnas.150770611310.1073/pnas.1507706113 ↗
24. 10.1038/nbt116110.1038/nbt1161 ↗
25. 10.1007/s40259-022-00549-310.1007/s40259-022-00549-3 ↗
26. 10.1038/nnano.2017.5210.1038/nnano.2017.52 ↗
27. 10.1038/nmat482210.1038/nmat4822 ↗
28. 10.1038/nature1297810.1038/nature12978 ↗
29. 10.1038/s41596-022-00755-x10.1038/s41596-022-00755-x ↗
30. 10.1126/scitranslmed.aaz666710.1126/scitranslmed.aaz6667 ↗
31. 10.1002/adma.20200180810.1002/adma.202001808 ↗
32. 10.1126/scitranslmed.adf530210.1126/scitranslmed.adf5302 ↗
33. 10.1126/scitranslmed.abj127010.1126/scitranslmed.abj1270 ↗
34. 10.3390/cancers1602028910.3390/cancers16020289 ↗
35. 10.4049/jimmunol.160077210.4049/jimmunol.1600772 ↗
36. 10.1093/intimm/13.5.67510.1093/intimm/13.5.675 ↗
37. 10.1002/adma.20190079510.1002/adma.201900795 ↗
38. 10.1038/s41565-021-00939-810.1038/s41565-021-00939-8 ↗
39. 10.1002/adhm.20190077210.1002/adhm.201900772 ↗
40. 10.1186/s12951-021-01085-y10.1186/s12951-021-01085-y ↗
41. 10.1021/acsnano.6b0314810.1021/acsnano.6b03148 ↗
42. 10.1038/s41587-022-01491-z10.1038/s41587-022-01491-z ↗
43. 10.1002/adma.20170396910.1002/adma.201703969 ↗
44. 10.1038/nri325410.1038/nri3254 ↗
45. 10.3390/cancers1315366710.3390/cancers13153667 ↗
46. 10.1016/j.jconrel.2022.10.00210.1016/j.jconrel.2022.10.002 ↗
47. 10.1021/acsami.2c0606510.1021/acsami.2c06065 ↗
48. 10.1038/s41467-019-12275-610.1038/s41467-019-12275-6 ↗
49. 10.1016/j.ymthe.2017.03.01310.1016/j.ymthe.2017.03.013 ↗
50. 10.1002/advs.20200110810.1002/advs.202001108 ↗
51. 10.1038/s41565-020-00782-310.1038/s41565-020-00782-3 ↗
52. 10.1038/nature2207910.1038/nature22079 ↗
53. 10.1038/s41571-021-00562-510.1038/s41571-021-00562-5 ↗
54. 10.1126/science.aav869210.1126/science.aav8692 ↗
55. 10.1126/science.aay596710.1126/science.aay5967 ↗
56. 10.1016/j.cell.2023.06.00210.1016/j.cell.2023.06.002 ↗
57. 10.1038/s43018-022-00418-610.1038/s43018-022-00418-6 ↗
58. 10.1038/s41423-023-00990-610.1038/s41423-023-00990-6 ↗
59. 10.1038/s41388-021-01946-810.1038/s41388-021-01946-8 ↗
60. 10.1039/D2CS00647B10.1039/D2CS00647B ↗
61. 10.1038/s41573-021-00163-y10.1038/s41573-021-00163-y ↗
62. 10.1016/j.it.2008.09.00610.1016/j.it.2008.09.006 ↗
63. 10.1073/pnas.080469910510.1073/pnas.0804699105 ↗
64. 10.1016/j.cell.2018.08.07010.1016/j.cell.2018.08.070 ↗
65. 10.3322/caac.2183410.3322/caac.21834 ↗
66. 10.1056/NEJMra203486110.1056/NEJMra2034861 ↗
67. 10.3389/fonc.2019.0114810.3389/fonc.2019.01148 ↗
68. 10.3389/fimmu.2017.0033110.3389/fimmu.2017.00331 ↗
69. 10.1039/D2BM01549H10.1039/D2BM01549H ↗